Telemedicine Fraud Defense
Former DOJ Fraud Section Prosecutors. Nationwide Defense for Telemedicine Company Owners, Telehealth Platform Operators, Physicians, Nurse Practitioners, MSO Executives, and Healthcare Professionals Facing Federal Telemedicine Fraud Investigations and Charges.
Based in Washington, D.C., Armstrong & Bradylyons PLLC defends telemedicine company owners, telehealth platform operators, physicians, nurse practitioners, management services organization (MSO) executives, call center operators, marketers, and healthcare executives in federal telemedicine fraud investigations and cases nationwide.
The firm’s healthcare fraud defense practice is built on nearly a decade of combined experience at the nation’s preeminent healthcare fraud enforcement unit: the Healthcare Fraud Unit of DOJ’s Fraud Section. Scott Armstrong, Drew Bradylyons, and Andrea Savdie tried 17 federal jury trials in healthcare fraud cases at DOJ’s Fraud Section involving over $2.8 billion in alleged false and fraudulent claims to federal healthcare programs. The firm uses that experience to defend individuals in telemedicine fraud cases at every stage: from the first grand jury subpoena, through federal indictment, and at trial.
Telemedicine fraud is one of the most aggressively prosecuted categories of healthcare fraud. DOJ has stated that telemedicine fraud schemes have “exploded” and present “grave fraud risks.” The firm defends individuals in every federal district where DOJ, HHS-OIG, and the DEA bring telemedicine fraud cases.
Armstrong & Bradylyons PLLC defends every telemedicine fraud case from the start as if it will go to trial. That is not a slogan. It is the operating principle of the firm, grounded in 25 federal jury trials in complex fraud cases in federal courts across the country.
Trial experience drives results at every stage. Telemedicine fraud cases are built on platform data, call center records, prescribing patterns, and cooperating witness testimony. They involve allegations that telemedicine encounters were sham consultations, that physician orders were generated without genuine patient relationships, that platforms influenced clinical decision-making to maximize billing, that kickbacks were paid for orders or prescriptions, and that controlled substances were prescribed without legitimate medical purpose. The firm builds the factual record from the first day of engagement: analyzing platform data, retaining clinical experts, identifying and preparing witnesses, and developing a case theory that can withstand the government’s scrutiny.
The firm’s attorneys know how federal prosecutors build healthcare fraud cases because they built them. Scott Armstrong served for nearly a decade at DOJ’s Fraud Section, where he tried 13 federal jury trials, 16 in all counting his trials before joining DOJ, including complex healthcare fraud cases involving Medicare, Medicaid, and Tricare. Drew Bradylyons served as Chief of EDVA’s Financial Crimes and Public Corruption Unit and, before that, supervised the Healthcare Fraud Unit’s Miami Strike Force at DOJ’s Fraud Section. That combined experience provides the firm with an unmatched understanding of how federal healthcare fraud cases are investigated, charged, and tried.
The firm relishes the opportunity to try cases. Its willingness to go to trial and its proven skills at trial provide significant leverage in negotiations with federal prosecutors at every stage of a telemedicine fraud case.
Telemedicine fraud has been a named federal enforcement priority since well before the pandemic. In 2019, DOJ launched Operation Brace Yourself, charging 24 defendants in telemedicine-driven schemes involving medically unnecessary DME and orthotic braces. That same year, Operation Double Helix charged 35 defendants in telemedicine-driven genetic testing fraud. Combined, these operations involved over $10 billion in alleged fraud. The enforcement has only accelerated since.
The 2026 National Health Care Fraud Takedown
On June 23, 2026, DOJ announced the 2026 National Health Care Fraud Takedown, the largest coordinated healthcare fraud enforcement action in the Department’s history. Prosecutors charged 455 defendants, including 90 doctors and other licensed medical professionals, in schemes involving over $6.5 billion in false claims. The cases span 56 federal districts across 45 states and territories, with 50 state Medicaid Fraud Control Units participating.
Telemedicine providers should read the 2026 Takedown carefully, because the headline category moved. Wound care allografts and Medicaid fraud drew the largest charges this year. Telemedicine did not fall off the enforcement agenda. It changed shape. Telemedicine exposure now runs primarily through two channels: transnational networks that use telehealth to generate durable medical equipment and genetic testing orders, and controlled substance prescribing conducted without meaningful practitioner contact.
The international dimension is new and it is aggressive. On June 4, 2026, the FBI created a Most Wanted Fraudsters List. The first fugitive named to it was wanted in a $1.2 billion telemedicine and durable medical equipment scheme. He was apprehended in the Philippines four days later and indicted in the District of South Carolina on three counts of failure to appear. In a separate matter, a defendant charged with an additional $3.7 billion in false claims for urinary catheters and other DME that was never provided fled the country and was apprehended in Kyrenia. Two members of the same transnational organization were extradited from Estonia. Flight is no longer a viable strategy in these cases.
A New Federal Enforcement Architecture
The institutional structure behind these cases changed in 2026. On April 7, 2026, DOJ created the National Fraud Enforcement Division. The Health Care Fraud Unit and the nine Health Care Fraud Strike Forces now operate within it. Since the Strike Force program began in March 2007, it has charged more than 6,200 defendants who collectively billed federal healthcare programs and private insurers more than $45 billion.
The analytics capability changed as well. The Health Care Fraud Unit’s Data Fusion Center, announced during the 2025 Takedown, drove many of the cases charged in 2026. DOJ also announced the first prosecution arising from the Fusion Center’s Financial Intelligence Review Team, a matter in which prosecutors opened an investigation within five days of the financial intelligence review and arrested the defendant less than seven months later. DOJ has now secured cloud computing space inside the CMS Integrated Data Repository to run advanced analytics and artificial intelligence tools directly against claims data, and has entered data-sharing agreements with the Department of Homeland Security and the Federal Trade Commission. The window between a billing anomaly and a federal inquiry is now measured in weeks.
Administrative Consequences Arrive First
The 2026 Takedown was accompanied by administrative action at a scale that dwarfs the criminal charges. CMS suspended 1,079 providers and revoked billing privileges for 1,403 more. HHS-OIG imposed over 1,400 provider exclusions and brought 25 actions under the Civil Monetary Penalties Law seeking more than $10 billion. The DEA brought 928 administrative cases seeking revocation of authority to handle or prescribe controlled substances since October 1, 2025.
For a telemedicine prescriber, that ordering matters. The payment suspension, the billing privilege revocation, or the DEA Order to Show Cause frequently lands months before any indictment. It is often the first sign that a criminal investigation exists at all.
Controlled Substance Prescribing Through Telehealth
In the 2026 Takedown, 36 defendants, including 28 licensed medical professionals, were charged in connection with the illegal diversion of prescription opioids and other controlled substances resulting in patient harm. One case is directly instructive for telehealth platforms. In the Eastern District of Pennsylvania, three defendants were charged for operating a voicemail refill line that allowed patients to request and receive refills of Schedule II prescriptions without any practitioner interaction. Some patients who used the line overdosed and died, and the defendants allegedly kept it running.
The theory in that case is the theory the government now applies to telehealth platforms: a prescription issued without genuine practitioner evaluation is not a prescription at all, but a distribution. Where practitioner contact is thin enough, DOJ charges under the Controlled Substances Act rather than the healthcare fraud statute.
Done Global remains the defining platform-level case. On July 7, 2026, the founder and former CEO was sentenced to 72 months in prison and fined $1 million, and the former clinical president was sentenced to 24 months and fined $1 million. DOJ described a $90 million scheme that used the company’s technology platform, compensation structure, and clinical protocols to unlawfully distribute over 37 million pills of Adderall, defraud insurers of more than $12 million, and obstruct the ensuing federal investigation. The evidence included auto-refill features that reduced clinical review after an initial diagnosis, protocols that penalized cautious clinicians, and a secondary entity allegedly created to bypass pharmacy blocks.
Sentences in Telemedicine Fraud Cases Are Severe
A telemedicine company owner was sentenced to seven years for a $56 million Medicare fraud scheme involving kickbacks for orthotic brace orders. Another operator received 10 years for a $174 million telemedicine fraud conspiracy. Sentencing exposure in these cases is driven by the loss calculation, and the loss calculation is usually the most contestable number in the case.
The Regulatory Cliff Is Approaching
DEA and HHS issued a fourth temporary extension of telemedicine flexibilities for controlled substance prescribing, effective through December 31, 2026. Practitioners may continue to prescribe Schedule II through V controlled medications through audio-video telemedicine without a prior in-person evaluation. A permanent framework, including the proposed special registration pathway for telemedicine prescribers and platforms, remains pending.
Two points follow. First, the current authority is temporary and expires at the end of this year, so arrangements built on it need a transition plan. Second, and more important, the flexibility was never a shield. DOJ charges telemedicine prescribing cases under 21 U.S.C. § 841, not under CMS billing rules. Whether an in-person visit was required is a different question from whether the prescription served a legitimate medical purpose. The regulatory environment is permissive. The enforcement environment is not.
In 2022, HHS-OIG issued a Special Fraud Alert identifying suspect characteristics of telemedicine arrangements, including limited patient contact, volume-based compensation, and restricted treatment offerings. That alert remains the government’s clearest published statement of the red flags it uses to identify telemedicine fraud targets.
The Firm Built These Cases
Armstrong & Bradylyons PLLC does not describe this enforcement landscape from the outside. The firm’s attorneys prosecuted a $1 billion fraud scheme at DOJ involving a telemedicine platform that generated false doctors’ orders used to bill Medicare. They oversaw and coordinated a nationwide enforcement action targeting medically unnecessary durable medical equipment prescribed through telehealth, a scheme that involved over $100 million in losses. They served as lead counsel in a $60 million scheme involving fraudulent Medicare claims for durable medical equipment that was medically unnecessary and procured through kickbacks and bribes.
Coordinated actions of the kind DOJ announced in June are assembled months in advance. Counsel who has run one knows how the government decides which conduct becomes a charge, which participant becomes a defendant, and which becomes a witness. That knowledge is most valuable before the charging decision is made.
The firm’s telemedicine fraud defense practice is built on healthcare fraud trial experience, deep knowledge of federal telehealth billing and prescribing regulations, and years of experience investigating and prosecuting complex healthcare fraud cases at DOJ’s Fraud Section. These tools are deployed at every phase of a case.
Establishing Legitimate Telemedicine Encounters and Physician-Patient Relationships
The government’s central theory in telemedicine fraud cases is that physician-patient relationships were nonexistent or insufficient. Prosecutors allege that physicians signed orders without examining, speaking to, or evaluating the patient. The firm builds the factual record to demonstrate that telemedicine encounters were genuine, that clinical evaluations met applicable standards of care, and that physician orders were based on individualized clinical assessment. The firm retains clinical experts to evaluate the quality and sufficiency of telemedicine consultations against the applicable standard of care and CMS telehealth billing requirements.
Defending Telehealth Platform Operators and MSO Executives
DOJ increasingly targets the platforms and management structures behind telemedicine operations, not just the physicians who sign orders. The government alleges that platform design, workflow automation, and financial incentive structures improperly influenced clinical decision-making. The firm defends platform operators and MSO executives by demonstrating that the technology supported, rather than supplanted, independent clinical judgment. The firm analyzes corporate practice of medicine (CPOM) compliance, MSO-physician contractual arrangements, and the separation between administrative and clinical functions.
Challenging the Government’s Per-Order Payment and Referral Theories
The government treats per-order or per-prescription compensation to telemedicine physicians as strong evidence of Anti-Kickback Statute violations. Prosecutors allege that physicians were paid to sign orders, not to evaluate patients. The firm analyzes compensation arrangements against AKS safe harbor regulations, evaluates fair market value, and demonstrates that physician compensation was for legitimate professional services. The firm also defends against allegations that telemedicine companies paid kickbacks to call centers, marketers, or DME suppliers for patient referrals.
Defending Controlled Substance Prescribing Through Telemedicine
Following the Done Global convictions and sentencings, DOJ has signaled that controlled substance prescribing through telemedicine is a top enforcement priority. The government alleges that telemedicine platforms facilitated prescribing without legitimate medical purpose, without adequate patient evaluation, or in quantities that exceeded clinical need. The firm defends physicians and platform operators by establishing the clinical basis for prescribing decisions, demonstrating compliance with DEA regulations and applicable state prescribing laws, and challenging the government’s characterization of legitimate telemedicine care as illegitimate distribution.
Federal telemedicine fraud investigations target individuals at every level of the operation: from the platform operators who build and control the technology, to the physicians who conduct consultations and sign orders, the call centers that recruit patients, and the downstream companies that bill for the products and services ordered through the platform. Armstrong & Bradylyons PLLC defends these individuals in federal investigations, after indictment, and at trial.
Defense of Telemedicine Company Owners and Platform Operators
The firm defends the founders, owners, and operators of telemedicine companies, telehealth platforms, and digital health companies in federal fraud, Anti-Kickback Statute, controlled substance distribution, and money laundering investigations and prosecutions. Platform operators are primary enforcement targets. Prosecutors pursue owners who allegedly designed platforms to generate fraudulent orders, created workflows that bypassed clinical oversight, paid kickbacks for orders or prescriptions, concealed the true nature of physician compensation, or used technology to eliminate evidence that might trigger Medicare audits. The firm defends platform operators by challenging the government’s evidence of personal knowledge, direction, and intent.
Defense of Physicians and Nurse Practitioners
The firm defends physicians, nurse practitioners, and other licensed medical professionals who face federal charges for signing orders or prescribing through telemedicine platforms. Medical professionals face criminal exposure when the government alleges they signed orders for patients they never examined, approved orders based only on brief phone calls or no patient contact, received per-order or per-prescription kickback payments, or prescribed controlled substances without legitimate medical purpose. The firm defends medical professionals by establishing the clinical basis for their orders and prescribing decisions, demonstrating the adequacy of their patient evaluations, and challenging the government’s characterization of legitimate telemedicine practice as fraudulent conduct.
Defense of MSO Executives and Investors
The firm defends management services organization (MSO) executives, corporate officers, and investors in telemedicine companies. DOJ’s Done Global prosecution established that MSO structures and corporate practice of medicine compliance are now part of the enforcement conversation. The firm defends MSO executives by demonstrating the legitimacy of management arrangements, the separation between administrative and clinical functions, and the absence of improper influence over clinical decision-making.
Defense of Call Center Operators and Marketers
The firm defends call center owners, telemarketing operators, and patient recruiters who face federal charges in telemedicine fraud cases. Call center operators face exposure when the government alleges they recruited patients through deceptive marketing, sold patient leads or signed orders to telemedicine companies or downstream suppliers, or received per-patient or per-lead kickback payments. The firm defends call center operators by challenging the government’s evidence of knowledge, intent, and the nature of the compensation arrangements.
Defense of DME Suppliers, Laboratories, and Pharmacies
The firm defends durable medical equipment suppliers, laboratory owners, and pharmacy operators who face federal charges for their participation in telemedicine fraud schemes. These downstream entities face exposure when the government alleges they paid kickbacks for orders generated through telemedicine platforms, submitted claims for products or services that were medically unnecessary, or billed for items that were never delivered. The firm defends these individuals by challenging the government’s evidence of their knowledge of and participation in the upstream fraud.
Federal telemedicine fraud investigations follow a pattern. Understanding that pattern is the first step to defending against it. Scott Armstrong and Drew Bradylyons built these types of cases as senior prosecutors at DOJ’s Fraud Section. They know how federal investigators identify targets, develop evidence, and present cases to grand juries.
Claims Data Analytics and Prescribing Pattern Analysis
The investigation typically begins with data. HHS-OIG, CMS, the FBI, and the DEA use claims data analytics to identify providers with anomalous billing or prescribing patterns. The government flags telemedicine providers who sign disproportionately high volumes of orders for DME, genetic testing, or controlled substances, whose prescribing patterns diverge from peer averages, who bill for telehealth consultations lasting only minutes, or whose patient populations are geographically dispersed in ways that suggest telemarketing-driven referrals. That capability expanded in 2026: DOJ now runs analytics and artificial intelligence tools inside the CMS Integrated Data Repository, and the Health Care Fraud Unit’s Data Fusion Center drove many of the cases charged in this year’s national Takedown.
Platform Data and Technology Analysis
Federal investigators increasingly target the technology itself. They analyze platform workflows, automated order-generation processes, scheduling algorithms, and clinical decision-support tools for evidence that the technology influenced or supplanted independent clinical judgment. Investigators examine whether the platform restricted treatment options, auto-populated clinical documentation, generated templated chart notes, or created financial incentives that pressured physicians to approve orders. Electronic health record metadata, login timestamps, and session duration data are critical evidence in these cases.
Physician Compensation and Kickback Tracing
The government traces every payment to telemedicine physicians. Investigators determine whether physicians were paid on a per-order, per-prescription, or per-consultation basis. Per-order and per-prescription compensation is treated as strong evidence of kickback violations under the Anti-Kickback Statute. Investigators also trace payments between telemedicine companies, call centers, DME suppliers, laboratories, and pharmacies to map the full referral chain and identify kickback arrangements at every level.
Patient and Physician Interviews
Federal agents interview patients to determine whether they actually spoke with a physician, whether they understood what they were agreeing to, and whether they received the products or services that were ordered on their behalf. Agents also interview physicians who worked on the platform to determine whether they conducted genuine clinical evaluations, whether they felt pressured to approve orders, and whether they understood the financial relationships underlying the platform. Physician cooperators are a cornerstone of telemedicine fraud prosecutions.
Call Center and Marketing Records
The government analyzes call center scripts, recorded calls, marketing materials, and lead-generation records. Investigators examine whether call center operators used deceptive marketing to recruit patients, whether patients were told their insurance would cover free products, and whether call center operators sold patient leads or signed orders to telemedicine companies or downstream suppliers. Call recordings are powerful trial evidence.
HHS-OIG Special Fraud Alert Red Flags
In 2022, HHS-OIG issued a Special Fraud Alert identifying characteristics of telemedicine arrangements that may implicate the Anti-Kickback Statute. The alert identifies the following red flags: patients identified or recruited by the telemedicine company, practitioners compensated based on the number of items or services ordered, limited or no patient interaction, restricted offerings of products or services, and limited follow-up with patients. These red flags are the government’s published roadmap for identifying telemedicine fraud targets.
Search Warrants and Electronic Evidence
Federal agents routinely seek and execute search warrants for cell phones, laptops, servers, and cloud-based accounts in telemedicine fraud investigations. These warrants target platform source code, call recordings, internal communications, financial records, and physician compensation data. Federal agents obtain cloud warrants under 18 U.S.C. § 2703 of the Stored Communications Act. Prosecutors use this evidence to show that operators scrubbed language from physician orders or varied chart note narratives to avoid triggering Medicare audits.
Federal telemedicine fraud prosecutions draw on several criminal statutes. Telemedicine cases are distinctive because they can invoke both traditional healthcare fraud statutes and controlled substance distribution charges. The government charges aggressively and stacks counts.
Healthcare Fraud (18 U.S.C. § 1347)
The primary charging statute in telemedicine fraud cases. Healthcare fraud makes it a federal crime to knowingly and willfully execute a scheme to defraud any healthcare benefit program. In telemedicine cases, this statute targets billing for consultations that were not genuine medical encounters, generating orders for products or services that were medically unnecessary, and submitting claims based on fraudulent physician orders. The penalty is up to 10 years of imprisonment per count. If the fraud results in serious bodily injury, the maximum increases to 20 years. If it results in death, a life sentence is possible.
Controlled Substances Act (21 U.S.C. § 841)
Following the Done Global prosecution, controlled substance distribution charges are an expanding enforcement vector in telemedicine fraud cases. 21 U.S.C. § 841 prohibits distributing or dispensing controlled substances except as authorized by a valid prescription issued for a legitimate medical purpose by a practitioner acting in the usual course of professional practice. When the government alleges that telemedicine prescribing lacked legitimate medical purpose, it charges distribution rather than healthcare fraud. Distribution of Schedule II controlled substances carries up to 20 years per count.
Wire Fraud (18 U.S.C. § 1343)
The government frequently charges wire fraud in telemedicine cases. Telemedicine operations are inherently wire-dependent: the consultations occur over electronic communications, the orders are transmitted electronically, and the claims are submitted electronically. Wire fraud carries a maximum penalty of 20 years of imprisonment per count.
Anti-Kickback Statute (42 U.S.C. § 1320a-7b)
The Anti-Kickback Statute is at the center of most telemedicine fraud prosecutions. It prohibits offering, paying, soliciting, or receiving anything of value to induce or reward referrals for services covered by federal healthcare programs. In telemedicine cases, prosecutors target per-order payments to physicians, payments to call centers for patient leads, payments between telemedicine companies and DME suppliers or laboratories, and kickbacks disguised as consulting fees or platform access charges. Violations carry up to 10 years of imprisonment per violation.
Money Laundering (18 U.S.C. §§ 1956, 1957)
Money laundering charges are common in large-scale telemedicine fraud prosecutions. The government charges money laundering when it alleges that defendants conducted financial transactions involving fraud proceeds with the intent to conceal or promote the underlying scheme. Money laundering carries up to 20 years of imprisonment per count.
False Claims Act (31 U.S.C. §§ 3729–3733)
The False Claims Act is the government’s primary civil enforcement tool. In telemedicine cases, the FCA targets claims generated through fraudulent telemedicine encounters and claims tainted by kickback relationships. Civil FCA enforcement in healthcare hit a historic high in FY 2025: over $6.8 billion in settlements. Many telemedicine investigations run parallel criminal and civil tracks.
Federal Program Exclusion and Collateral Consequences
Beyond incarceration and fines, a conviction or settlement triggers mandatory exclusion from Medicare, Medicaid, and all federal healthcare programs under the authority of HHS-OIG. For physicians and licensed professionals, exclusion effectively ends a career. DEA registration may be revoked if the case involves controlled substance prescribing. State licensing boards may initiate independent disciplinary proceedings.
What Is Telemedicine Fraud Under Federal Law?
Telemedicine fraud is not a single offense. It is a category of federal prosecution in which the government alleges that a telehealth encounter was used to generate a claim, an order, or a prescription that had no legitimate clinical basis. There is no statute titled “telemedicine fraud.” Prosecutors charge the conduct under existing statutes.
The recurring fact patterns are sham consultations used to generate orders for durable medical equipment or genetic testing, billing for telehealth encounters that involved no meaningful clinical evaluation, per-order or per-prescription compensation to practitioners, kickbacks paid to call centers for patient leads, and controlled substance prescribing without a legitimate medical purpose.
The charging statutes are 18 U.S.C. § 1347 (healthcare fraud), 18 U.S.C. § 1343 (wire fraud), 42 U.S.C. § 1320a-7b (Anti-Kickback Statute), 21 U.S.C. § 841 (controlled substance distribution), and the money laundering and conspiracy statutes. The firm’s attorneys prosecuted a $1 billion telemedicine platform scheme at DOJ and now defend against these same charges nationwide.
How Do I Know If I Am Under Federal Investigation for Telemedicine Fraud?
Most providers learn late, and the first signals are usually administrative rather than criminal. A CMS payment suspension, a prepayment review, a billing privilege revocation, a UPIC or ZPIC audit, or a records request from HHS-OIG can each mean that a criminal investigation is already open.
Other indicators include federal agents contacting current or former employees, a grand jury subpoena served on your billing company or a downstream supplier, a DEA administrative subpoena for prescribing records, and a sealed qui tam complaint you will not learn about until the government intervenes.
Investigations now start with data. The Health Care Fraud Unit’s Data Fusion Center drove many of the cases charged in the 2026 National Health Care Fraud Takedown, and DOJ runs analytics and artificial intelligence tools inside the CMS Integrated Data Repository. In the first prosecution from the Fusion Center’s Financial Intelligence Review Team, prosecutors opened the case within five days of the financial review. If any of these signals appear, retain federal defense counsel before responding.
What Should I Do If I Receive a Grand Jury Subpoena or Target Letter in a Telemedicine Case?
Do not produce documents, speak with agents, or contact the prosecutor before retaining counsel. Everything you say and every document you hand over becomes part of the government’s case, and the decisions made in the first two weeks frequently determine the outcome.
A subpoena duces tecum compels documents. A subpoena ad testificandum compels testimony. A target letter means the prosecutor believes there is substantial evidence linking you to a crime and considers you a putative defendant. Your status as a witness, subject, or target determines your exposure and your strategy, and that status can change based on what you produce and what you say.
Counsel assesses your status, asserts applicable privileges and Fifth Amendment rights, negotiates the scope of production, and moves to quash or limit the subpoena where appropriate. Scott Armstrong and Drew Bradylyons issued subpoenas and target letters of this kind as federal prosecutors, and they use that experience to evaluate where a client actually stands rather than where the government says they stand.
Can a Physician or Nurse Practitioner Be Charged for Signing Orders Through a Telemedicine Platform?
Yes, and licensed practitioners are charged routinely. Of the 455 defendants charged in the 2026 National Health Care Fraud Takedown, 90 were doctors and other licensed medical professionals. Of the 36 defendants charged in the Takedown’s controlled substance cases, 28 were licensed practitioners.
In Operation Brace Yourself, physicians who signed orders for orthotic braces without examining patients were charged and convicted. In Operation Happy Clickers, nurse practitioners who approved orders without reading them faced criminal and civil enforcement. The government treats a practitioner who signs high volumes of orders without genuine clinical evaluation as an active participant in the scheme, and treats per-order compensation as a kickback.
The defense establishes the clinical basis for the practitioner’s orders, documents the adequacy of the evaluation, and challenges the characterization of legitimate telehealth practice as rubber-stamping. The firm’s attorneys charged practitioners in these cases at DOJ, including in a $1 billion telemedicine platform prosecution, and know what separates a chargeable practitioner from a witness.
Can I Be Charged If I Did Not Know the Telemedicine Platform Was Fraudulent?
Yes, if the government can prove you deliberately avoided learning the truth. Federal prosecutors use willful blindness to establish knowledge, arguing that a defendant subjectively believed there was a high probability of fraud and took deliberate steps to avoid confirming it. Ignoring compliance warnings, declining to ask why order volume was implausible, or structuring a role to avoid visibility can all support that theory.
Controlled substance charges are different, and the difference favors prescribers. Under Ruan v. United States, 597 U.S. 450 (2022), once a practitioner produces evidence of authorized conduct, the government must prove the practitioner knew or intended that the prescribing was unauthorized. Good faith is a live issue, not an afterthought.
Defending these theories requires reconstructing what the client actually knew, when, and on what information. The firm builds that record from contemporaneous documents, compliance communications, and platform data rather than leaving the jury with the government’s inference.
What Defenses Are Available in a Federal Telemedicine Fraud Case?
The available defenses depend on the allegations, but six recur in nearly every telemedicine fraud case:
Legitimate clinical encounters. Evidence that consultations involved genuine patient evaluation consistent with the applicable standard of care.
Independent clinical judgment. Evidence that ordering and prescribing decisions were made independently, not driven by platform design or financial incentives.
Safe harbor compliance. Compensation arrangements that fall within recognized AKS safe harbors and reflect fair market value for professional services.
Attacking the data. DOJ runs analytics and artificial intelligence tools against CMS claims data. Those methodologies become summary exhibits at trial, and summary exhibits can be challenged on their inputs, assumptions, and exclusions.
Regulatory ambiguity. Evolving CMS, DEA, and state telehealth rules created genuine uncertainty about permissible billing and prescribing.
Cross-examining cooperators. Cooperating witnesses testify under plea agreements with sentencing incentives to implicate others.
Scott Armstrong served as lead trial counsel in the first data-analytics-driven healthcare prosecution DOJ ever tried, the direct antecedent of the analytics now deployed against telemedicine providers. He and Drew Bradylyons use that experience to anticipate the government’s trial strategy and build an evidence-based defense.
What Did the 2026 National Health Care Fraud Takedown Mean for Telemedicine Providers?
On June 23, 2026, DOJ announced the 2026 National Health Care Fraud Takedown, the largest in the Department’s history: 455 defendants, including 90 doctors and other licensed medical professionals, in schemes involving over $6.5 billion in false claims across 56 federal districts and 45 states and territories.
Three points matter for telemedicine providers. The headline category shifted to wound care allografts and Medicaid fraud, but telemedicine remains a flagged claim category and the infrastructure aimed at it is intact. Telemedicine exposure now runs heavily through transnational networks that use telehealth to generate DME and genetic testing orders, and the first fugitive named to the FBI’s new Most Wanted Fraudsters List, wanted in a $1.2 billion telemedicine and DME scheme, was apprehended in the Philippines four days after the list published. And the administrative consequences were enormous: 1,079 CMS provider suspensions, 1,403 billing privilege revocations, over 1,400 exclusions, and 928 DEA administrative cases.
The firm’s attorneys oversaw and coordinated a nationwide healthcare fraud enforcement action at DOJ targeting medically unnecessary durable medical equipment prescribed through telehealth, a scheme that involved over $100 million in losses. Coordinated actions are built months before the announcement, and understanding how they are assembled is what allows counsel to intervene while intervention still matters.
What Are the Penalties for a Federal Telemedicine Fraud Conviction?
The statutory maximums are severe. Healthcare fraud carries up to 10 years per count, and up to 20 years if the fraud causes serious bodily injury. Wire fraud carries up to 20 years per count. Controlled substance distribution carries up to 20 years per count. Money laundering carries up to 20 years per count. Anti-Kickback Statute violations carry up to 10 years per violation.
Actual sentences reflect that exposure. A telemedicine company owner received seven years for a $56 million scheme. Another operator received 10 years for a $174 million conspiracy. In July 2026, the founder of Done Global was sentenced to 72 months and fined $1 million, and the company’s former clinical president received 24 months and a $1 million fine.
The sentence is driven by the loss calculation under the Federal Sentencing Guidelines, and the loss figure is usually the most contestable number in the case. The firm’s attorneys built loss calculations of this kind as federal prosecutors, including in a $1 billion telemedicine platform prosecution and a $60 million DME scheme, and know where the assumptions inside them fail.
What Is the Statute of Limitations for Federal Telemedicine Fraud?
Five years for most federal telemedicine fraud charges. 18 U.S.C. § 3282 sets a five-year default for non-capital federal offenses, and healthcare fraud, wire fraud, Anti-Kickback Statute violations, and controlled substance distribution all fall within it.
Three qualifications matter. In a conspiracy, the clock runs from the last overt act, not from when the defendant joined, so a practitioner who stopped signing orders years ago can still be reached if the conspiracy continued. Wire fraud affecting a financial institution carries a ten-year period under 18 U.S.C. § 3293. And prosecutors routinely ask for tolling agreements, which counsel should evaluate carefully rather than grant reflexively.
Civil exposure runs longer. The False Claims Act allows six years from the violation, or three years after the material facts are known to the responsible government official, with an outer limit of ten years.
Will I Lose My Medical License or DEA Registration in a Telemedicine Fraud Investigation?
Your license and registration are at risk before any conviction, and often before any charge. Administrative action moves faster than criminal process and frequently arrives first.
Alongside the 2026 Takedown, CMS suspended 1,079 providers and revoked billing privileges for 1,403 more, HHS-OIG imposed over 1,400 exclusions, and the DEA brought 928 administrative cases seeking revocation of controlled substance authority. A DEA Immediate Suspension Order takes prescribing authority away on the spot, before any hearing. State licensing boards proceed independently.
These proceedings carry a trap. Statements and concessions made in an administrative or civil forum can be handed to criminal prosecutors, so the tracks must be defended together. The firm defends prescribers in DEA proceedings, including a nurse practitioner facing an Order to Show Cause and a physician assistant facing an Immediate Suspension Order, each arising from prescribing at a national telehealth-model testosterone clinic.
How Do Telemedicine Flexibilities Affect Federal Fraud Exposure?
They reduce regulatory barriers. They do not reduce enforcement risk, and providers who conflate the two are exposed. DEA and HHS issued a fourth temporary extension of telemedicine flexibilities for controlled substance prescribing, effective through December 31, 2026, permitting Schedule II through V prescribing by audio-video telemedicine without a prior in-person evaluation.
DOJ charges telemedicine prescribing cases under the Controlled Substances Act, not under CMS billing rules. Whether an in-person visit was required is a different question from whether the prescription served a legitimate medical purpose issued in the usual course of professional practice. The Done Global prosecution proceeded under the CSA while the flexibilities were in force.
Two practical consequences follow. The current authority expires at the end of this year and a permanent framework, including the proposed special registration pathway, remains pending, so arrangements built on the extension need a transition plan. And conduct occurring today will be judged later against professional practice standards, not against the temporary rule.
What Is the HHS-OIG Special Fraud Alert for Telemedicine?
It is the government’s published list of the red flags it uses to select telemedicine fraud targets. HHS-OIG issued the alert in 2022 to identify telemedicine arrangements that may implicate the Anti-Kickback Statute.
The five red flags are patients identified or recruited by the telemedicine company rather than seeking care on their own, practitioners compensated based on the number of items or services ordered, limited or no meaningful contact between practitioner and patient, offerings restricted to a narrow set of products or services, and little or no follow-up after the encounter.
An arrangement exhibiting several of these will draw scrutiny. The alert is not a safe harbor, and the absence of red flags is not a defense, but it remains the clearest available guide to how the government sorts legitimate telehealth from suspect arrangements.
What Did the Done Global Prosecution Establish for Telemedicine Enforcement?
It established that platform design is evidence. In November 2025, a federal jury in the Northern District of California convicted the founder and clinical president of Done Global, a subscription-based telehealth platform focused on ADHD treatment, in what DOJ described as the first criminal drug distribution prosecution arising from telemedicine prescribing practices.
On July 7, 2026, the founder was sentenced to 72 months in prison and fined $1 million, and the clinical president received 24 months and a $1 million fine. DOJ described a $90 million scheme involving the unlawful distribution of over 37 million pills of Adderall, more than $12 million in insurer fraud, and obstruction of the federal investigation.
The government’s theory reached the business model itself: corporate practice of medicine principles used as an evidentiary framework under the Controlled Substances Act, auto-refill features that reduced clinical review after an initial diagnosis, and protocols that penalized cautious clinicians. The 2026 Takedown confirmed the direction. Three defendants in the Eastern District of Pennsylvania were charged for operating a voicemail refill line issuing Schedule II refills with no practitioner interaction. Different technology, identical theory.
Does Armstrong & Bradylyons Handle Telemedicine Fraud Cases Nationwide?
Yes. Armstrong & Bradylyons PLLC defends individuals in federal telemedicine fraud investigations and prosecutions nationwide and can practice in every federal district court in the country.
The 2026 National Health Care Fraud Takedown brought cases in 56 federal districts across 45 states and territories. The Health Care Fraud Unit operates nine Strike Forces, including its National Rapid Response, Florida, Gulf Coast, Los Angeles, Midwest, New England, Northeast, Texas, and West Coast Strike Forces. Telemedicine prosecutions also originate from U.S. Attorney’s Offices well beyond the Strike Force footprint, including the Northern District of California, where the Done Global convictions were returned.
Scott Armstrong and Drew Bradylyons tried healthcare fraud cases and handled investigations in federal courts throughout the country during their combined 25-year DOJ career. The firm is based in Washington, D.C. and represents clients in every jurisdiction where DOJ, HHS-OIG, and DEA investigate and prosecute telemedicine fraud cases.